Last updated: February 11, 2026
What is the scope of the litigation?
Hospira Inc. filed suit against Par Sterile Products LLC in the United States District Court for the District of Delaware. The case revolves around patent infringement claims related to injectable drug products. Hospira alleges that Par Sterile’s devices infringe upon its patents covering sterile injectable drug delivery systems.
Which patents are involved?
Hospira asserts multiple patents, specifically:
- U.S. Patent No. 8,844,651, relating to a sterile injectable product with a specific glass container and closure system.
- U.S. Patent No. 8,918,906, covering certain features of a sterile drug container and method of manufacturing.
- U.S. Patent No. 9,346,862, focused on sterile drug vial closure arrangements.
These patents encompass the design and manufacturing processes intended to maintain sterility and product integrity.
What are the key allegations?
Hospira claims that Par Sterile’s pre-filled syringe products infringe on its patents via the following mechanisms:
- Use of similar vial closure systems.
- Incorporation of features claimed in the patents concerning the configuration of rubber stoppers and flange arrangements.
- Manufacturing processes that allegedly replicate patented methods to preserve product sterility.
Hospira seeks injunctive relief, damages, and a declaration of patent infringement.
What procedural history does the case exhibit?
Initial filings occurred in 2016, with the complaint filed on February 17, 2016, and served on Par Sterile. The defendant filed a motion to dismiss in 2017, challenging the patent claims and asserting defenses of non-infringement and invalidity based on prior art.
Discovery extended into 2018, involving document exchanges, deposition of witnesses, and technical analyses. A Markman hearing to interpret patent claim terms was held in 2018, resulting in court rulings narrowing the scope of certain patent claims.
Pre-trial motions included summary judgment motions, with notable decisions related to patent validity and infringement. The trial was scheduled for 2019 but was delayed due to settlement discussions.
Has the case settled or proceeded to litigation?
As of the latest publicly available updates, the case remained unresolved, with ongoing negotiations and possible settlement discussions reported. No court judgment or final resolution has been publicly recorded.
What are key legal issues?
- Claim construction: How the court interprets the patent claims, particularly regarding the scope of closure system features.
- Invalidity challenges: Par Sterile argued that some patents were anticipated or obvious based on prior art references.
- Infringement disputes: Whether Par Sterile’s products meet all elements of the patent claims.
What are strategic implications?
Hospira’s patent portfolio in sterile drug delivery methods and containers remains a critical set of assets. The case underscores the importance of securing broad patent claims and clear claim language to withstand invalidity defenses.
Par Sterile’s defenses focus on prior art and claim interpretation, emphasizing the need for precise patent drafting and thorough prior art searches during prosecution.
Summary of key dates:
| Date |
Event |
| Feb 17, 2016 |
Complaint filed |
| 2017 |
Motion to dismiss filed |
| 2018 |
Claim construction hearing and discovery phase |
| 2019 |
Scheduled trial, postponed possibly due to settlement |
Key Takeaways
- The litigation involves complex patent infringement issues centered on sterile injectable drug container systems.
- The outcome depends on claim construction, validity, and infringement determinations.
- The case underscores the importance of precise patent drafting in the pharmaceutical device space.
- As of the latest updates, no final judgment exists; ongoing settlement discussions could influence future patent enforcement strategies.
FAQs
Q1: What is the primary patent involved in this case?
Primarily, U.S. Patent No. 8,844,651, related to sterile injectable containers, is the centerpiece of the infringement claims.
Q2: Did the court find any patents invalid or enforceable?
No final rulings on validity or enforceability have been publicly reported.
Q3: Has the case settled?
No settlement has been publicly disclosed; the case remains open.
Q4: What is the significance of claim construction in this case?
Claim construction determines the scope of patent rights and can make or break infringement and validity defenses.
Q5: How could this case impact the sterile drug delivery market?
Legal disputes highlight the importance of patent strength and can influence licensing, development strategies, and market entry.
References:
- Court docket for Hospira Inc. v. Par Sterile Products LLC, 1:16-cv-00879, District of Delaware.
- Public court records and filings, accessed 2023.
(End of summary)
